» Articles » PMID: 3247301

Capillary Gas Chromatography and Thermionic N-P-specific Detection of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) or 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in Stability and Pharmacokinetic Studies

Overview
Journal Pharm Res
Specialties Pharmacology
Pharmacy
Date 1988 Apr 1
PMID 3247301
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

An expedient, rapid, and sensitive capillary gas chromatographic method for the analysis of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) or 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in plasma is described. Separation of the underivatized nitrosourea compounds was performed on a 0.33-mm-i.d., 25-m fused-silica, SE-30 capillary column, and detection was carried out using a thermionic N-P-specific detector. The compounds were extracted from plasma with benzene with a yield of greater than 87%. The assay was linear in the ranges of 0.001 to 0.5 and 0.5 to 25 micrograms/ml for CCNU or 0.003 to 0.50 and 0.5 to 25 micrograms/ml for BCNU, with correlation coefficients from 0.9914 to 0.9999 and coefficients of variation (CV) of less than 3.3%. Other antineoplastic agents did not interfere in the assay. The method was employed to study the pharmacokinetics of BCNU in rabbits. The plasma concentration-time curves were fit to a two-compartment model with a mean (SE) alpha, beta, and total-body clearance of 2.898 (0.913) hr-1, 0.1228 (0.0179) hr-1, and 7.211 (2.862) liters/hr.kg, respectively. Further, the stability of BCNU and CCNU in solution was examined at different temperatures. Both compounds were stable in benzene or acetone (4 to 37 degrees C) but labile in plasma even if refrigerated. The apparent rate constants for degradation of BCNU and CCNU were 0.09921 and 0.02853 hr-1 at 4 degrees C and 5.998 and 2.553 hr-1 at 37 degrees C, respectively.

Citing Articles

HPLC method validation for the quantification of lomustine to study pharmacokinetics of thermosensitive liposome-encapsulated lomustine containing iohexol for CT imaging in C6 glioma rats.

Zhuang L, Gao J, Zeng Y, Yu F, Zhang B, Li M Eur J Drug Metab Pharmacokinet. 2011; 36(2):61-9.

PMID: 21380568 DOI: 10.1007/s13318-011-0030-4.

References
1.
GREENBERG H, ENSMINGER W, Seeger J, Kindt G, Chandler F, Doan K . Intra-arterial BCNU chemotherapy for the treatment of malignant gliomas of the central nervous system: a preliminary report. Cancer Treat Rep. 1981; 65(9-10):803-10. View

2.
El-Yazigi A, Sawchuk R . Theophylline absorption and disposition in rabbits: oral, intravenous, and concentration-dependent kinetic studies. J Pharm Sci. 1981; 70(4):452-6. DOI: 10.1002/jps.2600700429. View

3.
Hochberg F, Parker L, Takvorian T, Canellos G, Zervas N . High-dose BCNU with autologous bone marrow rescue for recurrent glioblastoma multiforme. J Neurosurg. 1981; 54(4):455-60. DOI: 10.3171/jns.1981.54.4.0455. View

4.
Smith R, Blackstock S, Cheung L, Loo T . Analysis for nitrosourea antitumor agents by gas chromatography--mass spectrometry. Anal Chem. 1981; 53(8):1205-8. DOI: 10.1021/ac00231a017. View

5.
Krull I, Strauss J, Hochberg F, Zervas N . An improved trace analysis for N-nitrosoureas from biological media. J Anal Toxicol. 1981; 5(1):42-6. DOI: 10.1093/jat/5.1.42. View